Previous Close | 0.1234 |
Open | 0.1225 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.1215 - 0.1270 |
52 Week Range | 0.0840 - 0.4260 |
Volume | |
Avg. Volume | 228,771 |
Market Cap | 22.39M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0830 |
Earnings Date | Nov 22, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Europe and Latin America, continues to demonstrate its market dominance in the UK's medical cannabis industry with cannabis sales volume growth of 240% in Q1 2022 compared to the entire 2021 year. This growth is generated by Khiron's end-to-end solution of government regulation, supply chain, distribution, and clinics prescribing Khiron's
Khiron Life Sciences Corp. ("Khiron" or the "Corporation") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe, announced today its financial results for the year ended and quarter ended December 31, 2021. These filings are available for review on the Corporation's SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe, today announces that it will host a conference call on Monday, May 2nd , 2022 at 10:00 a.m. Eastern Time to discuss its financial results for year ended and quarter ended December 31, 2021. The Company will press release its financial results prior to the conference call. These filings will be available for review